エストロゲンブロッカーの世界市場レポート 2024年

エストロゲンブロッカー市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は7.3％で、123億7,000万米ドルに成長します。予測期間中に予想される成長は、乳がんの有病率の増加、認知度の向上とスクリーニングの取り組み、世界のエストロゲン関連疾患の増加、がん治療以外のエストロゲンブロッカーの使用拡大などに起因しています。この成長を促進すると予想される主要動向には、エストロゲンブロッカーの開発における主要開発、有効性を高めた新規阻害剤の発見、市場参入企業間の戦略的提携、新製品の承認などが含まれます。

乳がんの罹患率の増加は、エストロゲンブロッカー市場の成長を促進すると予測されています。乳がんは、主に乳管と小葉に影響を及ぼす乳房組織から発生し、制御不能な成長と腫瘍形成につながる正常な乳房細胞の突然変異から生じる。乳がん患者の増加は、人口の高齢化、アルコール消費量の増加や座りがちな行動などのライフスタイルの変化、先進的スクリーニングや診断方法による発見の向上などの要因に起因しています。エストロゲンブロッカーは、特定の乳がん細胞の増殖を促進するホルモンであるエストロゲンを阻害することにより、乳がん治療に使用されます。これらの阻害剤は、ホルモン受容体陽性の乳がんの成長を遅らせたり止めたりする効果があり、治療を助け、再発のリスクを低減する可能性があります。例えば、2024年1月、オーストラリア保健福祉ラボは、2023年に女性で2万458例の乳がんが診断され、年齢標準化罹患率は女性10万人当たり128.6例であったと報告しました。これは、2022年に診断された2万4症例（年齢標準化罹患率は女性10万人当たり128.2症例）からわずかな増加です。この有病率の上昇は、エストロゲン遮断薬市場の成長を促進すると予想されます。

エストロゲンブロッカー市場の各社は、乳がん治療における治療効果の向上と耐性への対処を目的として、AKT（プロテインキナーゼB）阻害剤と選択的エストロゲン受容体分解剤（SERD）を組み合わせた先進薬の開発に注力しています。この併用療法は、がん細胞の生存経路を標的とし、エストロゲン受容体を分解することで、腫瘍の増殖を抑制し、ホルモン治療に対する耐性を克服することを目指します。例えば、2023年11月、英国の製薬会社AstraZenecaは、SERDであるファスロデックス（フルベストラント）と併用するAKT阻害剤トゥルーカップ（capivasertib）のFDA承認を取得しました。この承認は、ホルモン受容体（HR）陽性、HER2陰性の局所進行性または転移性乳がんで、PIK3CA、AKT1、PTENなど特定のバイオマーカー変化を有する成人患者の治療に対するものです。これは特に、少なくとも1つの内分泌療法で進行した患者、または術後補助療法終了後12ヶ月以内に再発を経験した患者を対象としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のエストロゲンブロッカー市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のエストロゲンブロッカー市場の実績：規模と成長、2018～2023年
• 世界のエストロゲンブロッカー市場の予測：規模と成長、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のエストロゲンブロッカー市場：製品別、実績と予測、2018～2023年、2023～2028年、2033年
• 選択的エストロゲン受容体モジュレーター（SERM）
• アロマターゼ阻害剤
• エストロゲン受容体ダウンレギュレーター（ERD）
• その他
• 世界のエストロゲンブロッカー市場：流通チャネル別、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のエストロゲンブロッカー市場：用途別、実績と予測、2018～2023年、2023～2028年、2033年
• 乳がん治療
• ホルモン補充療法（HRT）
• 不妊治療
• 閉経後骨粗鬆症
• その他

第7章 地域別・国別分析

• 世界のエストロゲンブロッカー市場：地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のエストロゲンブロッカー市場：国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エストロゲンブロッカー市場：競合情勢
• エストロゲンブロッカー市場：企業プロファイル
  • Pfizer Inc
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc
  • Novartis AG
  • Sanofi S.A

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• GlaxoSmithKline plc
• Eli Lilly and Company
• Viatris Inc
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Ipsen S.A.
• Cadila Pharmaceuticals Ltd.
• Intas Pharmaceuticals Limited
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals Inc.
• Lupin Limited
• Glenmark Pharmaceuticals Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在的な分析

第36章 付録

Estrogen blockers are substances that inhibit the effects of estrogen in the body by either binding to estrogen receptors or reducing estrogen production. They are primarily used to treat estrogen receptor-positive breast cancer by preventing estrogen from promoting cancer cell growth. Additionally, estrogen blockers help manage conditions such as gynecomastia in men, endometriosis, and certain types of infertility by adjusting hormone levels.

The main types of estrogen blockers include selective estrogen receptor modulators (SERMs), aromatase inhibitors, estrogen receptor downregulators (ERDs), and other related substances. SERMs are a class of drugs that interact with estrogen receptors, acting as estrogen agonists in some tissues and antagonists in others. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used for various applications such as treating breast cancer, hormone replacement therapy (HRT), infertility treatment, post-menopausal osteoporosis, and other conditions.

The estrogen blockers market research report is one of a series of new reports from The Business Research Company that provides estrogen blockers market statistics, including estrogen blockers industry global market size, regional shares, competitors with an estrogen blockers market share, detailed estrogen blockers market segments, market trends and opportunities, and any further data you may need to thrive in the estrogen blockers industry. This estrogen blockers market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The estrogen blockers market size has grown strongly in recent years. It will grow from $8.72 billion in 2023 to $9.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed during the historic period can be attributed to a rise in prostate cancer prevalence, an increase in hormone-related disorders, and greater adoption of hormone replacement therapy (HRT).

The estrogen blockers market size is expected to see strong growth in the next few years. It will grow to $12.37 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth during the forecast period can be attributed to the increasing prevalence of breast cancer, growing awareness and screening initiatives, a rise in estrogen-related conditions worldwide, and the expanding use of estrogen blockers beyond cancer treatment. Key trends expected to drive this growth include advancements in the development of estrogen blockers, the discovery of novel blockers with enhanced efficacy, strategic partnerships among market players, and new product approvals.

The increasing incidence of breast cancer is projected to drive the growth of the estrogen blocker market. Breast cancer originates in the breast tissue, primarily affecting the milk ducts and lobules, and arises from mutations in normal breast cells that lead to uncontrolled growth and tumor formation. The rise in breast cancer cases can be attributed to factors such as an aging population, lifestyle changes such as higher alcohol consumption and sedentary behavior, and improved detection through advanced screening and diagnostic methods. Estrogen blockers are used in breast cancer treatment by inhibiting the hormone estrogen, which can fuel the growth of certain breast cancer cells. These blockers are effective in slowing or halting the growth of hormone receptor-positive breast cancers, aiding in treatment and potentially reducing the risk of recurrence. For instance, in January 2024, the Australian Institute of Health and Welfare reported that 20,458 cases of breast cancer were diagnosed in females in 2023, reflecting an age-standardized incidence rate of 128.6 cases per 100,000 females. This is a slight increase from the 20,004 cases diagnosed in 2022, with an age-standardized incidence rate of 128.2 cases per 100,000 females. This rising prevalence is expected to fuel growth in the estrogen blocker market.

Companies in the estrogen blocker market are concentrating on developing advanced drugs that combine AKT (Protein Kinase B) inhibitors with selective estrogen receptor degraders (SERDs) to improve treatment efficacy and address resistance in breast cancer therapy. This combination therapy targets survival pathways in cancer cells and degrades estrogen receptors, aiming to inhibit tumor growth and overcome resistance to hormonal treatments. For example, in November 2023, AstraZeneca, a UK-based pharmaceutical company, received FDA approval for Truqap (capivasertib), an AKT inhibitor, used in conjunction with Faslodex (fulvestrant), a SERD. This approval is for treating adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with specific biomarker alterations, such as PIK3CA, AKT1, or PTEN. This is particularly notable for patients who have progressed on at least one endocrine-based therapy or experienced recurrence within 12 months after completing adjuvant therapy.

In July 2024, Exscientia, a UK-based biotechnology company, acquired GT Apeiron's stake in its oral CDK7 inhibitor program for an undisclosed amount. This acquisition enhances Exscientia's oncology portfolio and positions the company to expand into combination therapies for HR+/HER2- breast cancer by late 2024. This development aligns with Exscientia's commitment to AI-driven drug design aimed at developing highly effective cancer treatments. GT Apeiron is a US-based expert in applied artificial intelligence and drug discovery, providing valuable expertise to support Exscientia's initiatives

Major companies operating in the estrogen blockers market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc, Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals Limited, Alvogen Inc., Alembic Pharmaceuticals Limited, Olema Pharmaceuticals Inc, Cipla Inc, Criterium Inc

North America was the largest region in the estrogen blockers market in 2023. The regions covered in the estrogen blockers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the estrogen blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The estrogen blockers market consists of sales of tamoxifen, raloxifene, toremifene, anastrozole, letrozole, exemestane, and fulvestrant. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Estrogen Blockers Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on estrogen blockers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for estrogen blockers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The estrogen blockers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Downregulators (ERDs); Other Products
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Application: Breast Cancer Treatment; Hormone Replacement Therapy (HRT); Infertility Treatment; Post-Menopausal Osteoporosis; Other Applications
• Companies Mentioned: Pfizer Inc; F. Hoffmann-La Roche AG; Merck & Co. Inc; Novartis AG; Sanofi S.A
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Estrogen Blockers Market Characteristics

3. Estrogen Blockers Market Trends And Strategies

4. Estrogen Blockers Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Estrogen Blockers Market Size and Growth

• 5.1. Global Estrogen Blockers Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Estrogen Blockers Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Estrogen Blockers Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Estrogen Blockers Market Segmentation

• 6.1. Global Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• Estrogen Receptor Downregulators (ERDs)
• Other Products
• 6.2. Global Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Breast Cancer Treatment
• Hormone Replacement Therapy (HRT)
• Infertility Treatment
• Post-Menopausal Osteoporosis
• Other Applications

7. Estrogen Blockers Market Regional And Country Analysis

• 7.1. Global Estrogen Blockers Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Estrogen Blockers Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Estrogen Blockers Market

• 8.1. Asia-Pacific Estrogen Blockers Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Estrogen Blockers Market

• 9.1. China Estrogen Blockers Market Overview
• 9.2. China Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Estrogen Blockers Market

• 10.1. India Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Estrogen Blockers Market

• 11.1. Japan Estrogen Blockers Market Overview
• 11.2. Japan Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Estrogen Blockers Market

• 12.1. Australia Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Estrogen Blockers Market

• 13.1. Indonesia Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Estrogen Blockers Market

• 14.1. South Korea Estrogen Blockers Market Overview
• 14.2. South Korea Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Estrogen Blockers Market

• 15.1. Western Europe Estrogen Blockers Market Overview
• 15.2. Western Europe Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Estrogen Blockers Market

• 16.1. UK Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Estrogen Blockers Market

• 17.1. Germany Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Estrogen Blockers Market

• 18.1. France Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Estrogen Blockers Market

• 19.1. Italy Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Estrogen Blockers Market

• 20.1. Spain Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Estrogen Blockers Market

• 21.1. Eastern Europe Estrogen Blockers Market Overview
• 21.2. Eastern Europe Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Estrogen Blockers Market

• 22.1. Russia Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Estrogen Blockers Market

• 23.1. North America Estrogen Blockers Market Overview
• 23.2. North America Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Estrogen Blockers Market

• 24.1. USA Estrogen Blockers Market Overview
• 24.2. USA Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Estrogen Blockers Market

• 25.1. Canada Estrogen Blockers Market Overview
• 25.2. Canada Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Estrogen Blockers Market

• 26.1. South America Estrogen Blockers Market Overview
• 26.2. South America Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Estrogen Blockers Market

• 27.1. Brazil Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Estrogen Blockers Market

• 28.1. Middle East Estrogen Blockers Market Overview
• 28.2. Middle East Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Estrogen Blockers Market

• 29.1. Africa Estrogen Blockers Market Overview
• 29.2. Africa Estrogen Blockers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Estrogen Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Estrogen Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Estrogen Blockers Market Competitive Landscape And Company Profiles

• 30.1. Estrogen Blockers Market Competitive Landscape
• 30.2. Estrogen Blockers Market Company Profiles
  • 30.2.1. Pfizer Inc
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi S.A
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Estrogen Blockers Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Viatris Inc
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Fresenius Kabi AG
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. Ipsen S.A.
• 31.9. Cadila Pharmaceuticals Ltd.
• 31.10. Intas Pharmaceuticals Limited
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. Amneal Pharmaceuticals Inc.
• 31.14. Lupin Limited
• 31.15. Glenmark Pharmaceuticals Limited

32. Global Estrogen Blockers Market Competitive Benchmarking

33. Global Estrogen Blockers Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Estrogen Blockers Market

35. Estrogen Blockers Market Future Outlook and Potential Analysis

• 35.1 Estrogen Blockers Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Estrogen Blockers Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Estrogen Blockers Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer